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1106-120 lmmunomodulatory Effects of Growth Hormone 
Administration Are Associated With Improvement in 
Myocardial Contractile Performance in Dilated 
Cardiomyopathy Patients 
Stamatis Adamopoulos, John T. Par&is, John Paraskevaidis, Dimitrios Karatzas. 
Christos Krouois. Eftimios Livanls. Georoe Karavokas. Dlmitrios T. Kremastinos. Onassis 
Cardiac Surgery Center, Athens, Greece, Amalia Fleming Hospital, Athens, Greece 
Objectives: ‘Ib study the immunomodulatory effects of growth hormone (GH) and to 
investigate whether these effects are associated with the improvement of left ventricular 
(LV) contract& performance in dilated cardiomyopathy (DC) patients (pts). 
Background: Recent studies indicate that an abnormal immune response contributes to 
the progression of chronic heart failure (CHF). 
Methods: Plasma inflammatory cyiokines TNFa. IL-6, GM-CSF, its soluble receptor 
sGM-CSFR and MCP-I, soluble adhesion molecules slCAM-1 and sVCAM-I, and anti- 
inflammatory cytokines IL-10 and TGF-P were measured (EL&A) in 12 DC pts (NYHA III; 
LVEF:24+3%) before and after a 3-month subcutaneous administration of GH 4lU every 
other day (randomized crossover design). Peak oxygen uptake (VO2 max). end-systolic 
wall stress (ESWS), mean velocity of circumferential fiber shortening (Vdc) and contrac- 
tile reserve (change of VcfclESWS after dobutamine infusion) were also determined. 
Resulte: GH produced a significant reduction in plasma TNFa (7.6kl.l vs 5.4kO.9 pg/ 
ml, pcO.Ol), IL-6 (5.6*0.5 vs 4X+0.3 pgiml, p<O.O5), GM-CSF (27*2 vs 23+2 pgiml, 
p<O.O5), sGM-CSFR (4.OkO.4 vs 3.210.3 ng/ml, ~~0.05). MCP-1 (199*5 vs 182*6 pg/ml, 
p<O.O5), slCAM-1 (324+33 vs 274*27 ng/ml, ~~0.05) and #/CAM-l (1237&6 vs 
1043+77 nglml, pc0 05), a?. well as a significant increase in ratio IL-lO/TNF-a (1.9kO.3 vs 
3.5+0.9, pcO.O5), IL-IO/IL-6 (2.620.6 “s 3.2tO.5, ~~0.05) and TGF-P/TNFa (3.1kO.6 “s 
4 4eO.6, p=O 05) in DC pts A significant reduction of ESWS (840+43 vs 634*41 gr/cm’. 
p<O.O05), and a significant increase of contractile reserve (0.0003~0.0001 vs 
0.0005~0.0001 circ’cr&gr’sec. p<O.OOi) and V02 max (15.2r0.7 vs 17.1*0.9 ml/kg/ 
mm, p<O.OOl) were also observed. Good correlations were found between GH-induced 
increase in contractile reserve and the increase in V02 max (r=0.62. ~~0.05). ratio IL-IO/ 
TNF-a (r=0.66. p&05) and TGFWNF-a (r=0.56, p<O.O5), as well as the reduction in 
TNF-a levels (r=-0.86, p<O 001). 
Conclusions: GH modulates beneficially cytokine network in DC pts. These immuno- 
modulatory effects may be associated with the improvement in LV contractile perfor- 
mance and exercise capacity of pts wth CHF and DC. 
1106-121 Beneficial Effects of High Doses of Growth Hormone in 
the Optimization of Medical Treatment in 
Decompensated Congestive Heart Failure 
Edimar A. Bocchi, Lidla Z. Moura, Gullherme GuimarBes, Giovanni V. Bellotti, Jose F. 
Ramires, Heart Institute (InCor), University of SBo Paula MedIcal School, SBo Paula, 
Brazil 
Background:Optimizing oral therapy m patients with advanced congestwe heart fail- 
ure(CHF)and cardiac cache& with unstable decompensated and/or dobutamine - 
dependent clinical status is a challenge. 
Methods:We investigated the effects of high doses of recombinant human growth hor- 
mone(GH) in hospitalized 5 patients(pts)with cardiac cachexla and unstable decompen- 
sated CHF(4 dobutamine-dependent) under maximal tolerated medical treatment. Pts 
recewed 6 IU of subcutaneous GH per day. 
Results:(Table)(‘pc.O06),(#p<.Oi) (pre= before GH use, after= after GH use, l&=6-12 
months after GH use),(systemic blood pressure=SBP), (left ventricular ejection frac- 
tion=LVEF)(MUGA).(LV end diastolic diameter=LVEDD (Echo).The NYHA functional 
class improved from IV to I in Ppts, from IV to II in 2, and from IV to 11-111 in l.All pts were 
discharged from the hospitaLIt was possible to optimize long-term CHF treatment with up 
to 50 mg of carvedilol in 4 pts and higher doses of captopril(l50 mg) in all patients.Two 
pts are alive after 40 and 46 months of follow-up.The remaining 3 pts died from a pulmo- 
nary abscess at 9 months, septicemia at 21 months. and unplanned withdrawal of 
carvedilol at 36 months. 
Conclusion:The use of GH in pts with decompensated CHF and cardiac cachexia can 
provide clinical stability without the need for motropic drugs. This could represent a new 
optlon for optimizing long-term CHF life-prolonging oral drug therapy and discharging 
hospitalized patients who are dobutamine-dependent. 
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1106-122 First Demonstration in Humans of Systemic Neutral 
Endopeptidase and Endothelin Converting Enzyme 
Inhibition Using a New Orally Active Dual 
Metalloprotease Inhibitor SLV 306 
Alison Seed Rhoda Kuc, Anthony Davenport, Michael Ashby, Chris Hillier, Hanka De 
Voogd, Hans Essers, John McMurray, University of Glasgow, Glasgow, United Kingdom 
Background: Simultaneous manipulation of several endogenous neurohumoral systems 
IS a new and promising therapeutic approach in hypertension and heart failure. SLV 306, 
through its active metabolite KC 12615, has dual neutral endopeptidase (NEP) and 
endothelin converting enzyme (ECE) inhibiting actiwty in vitro and in experimental ani- 
mals. The aim of this study was to demonstrate these actions in humans. 
Methods: 13 healthy males (mean age 23 years, range 19.38) were studied on 4 occa- 
sions with 1 week apart Subjects were randomised to placebo or one of 3 doses of SLV 
306. A double-blind ascending dose protocol with random insertton of placebo was 
employed. The 3 doses were chosen after a pharmacokinetic study in the same subjects, 
to obtain average plasma concentrations of KC 12615 of 75 (dose 1). 300 (dose 2) and 
1200 (dose 3) nglml. Subjects attended for a 7.hour study involving, in sequence, taking 
a single dose of SLV or placebo, supine rest (3 hours) and infusions of 6 and 12 pmollkgt 
min of big ET-l (20 minutes each). Systolic and diastolic blood pressure (SBP. DBP), 
atria1 natriuretic peptide (ANP), big endothelin-1 (big ET-l) and its cleavage product 
through the action of ECE on big ET-l, ET-l, were measured over 4 hours. 
Results: Mean peak changes in SBP (mmHg)after the second big ET-l infusion 
were:19.4 (placebo),l6.5 (dose 1),14.6 (dose 2), 12.9 (dose 3) (PsO.05). The respective 
changes in DBP were 16.2, 14.3, 12.0 and 11.4 (P<O.O5). The mean, placebo corrected, 
peptide changes over one hour following the second big ET-l infusion for doses 1, 2 and 
3 were; ANP: 7, 11, 15 pg/mL (p<O.Ol), big ET-l: 33,89, 121 fmol/mL (p<O.Ol) and ET- 
1: 0.95, 0.56, 0.02 fmoliml. ET-l levels did not increase as would have been expected 
from a pure NEP-inhibitor, whereas big ET-l levels were increased dose dependently in 
the SLV 306 groups compared to placebo, indicating that the breakdown of big ET-1 was 
inhiblted. SLV 306 was well tolerated. 
Conclusions: This is the first demonstration I” humans of both systemic endothelin con- 
verting enzyme and NEP Inhibition. SLV 306, the lead orally active agent in this new 
class of combined metalloprotease inhibitors, may have therapeutic potential in hyper- 
tension and heart failure. 
1106-123 Hyperkalemia and Impaired Renal Function During 
Treatment With Spironolactone in Patients With 
Congestive Heart Failure: Figures From a Real World 
Scenario 
Marten Svensson, Finn Gustafsson, Soeren Galatius, Dan Atar, Per R. Hildebrandt. 
Frederiksberg University Hospital, Frederiksberg-Copenhagen, Denmark, Aker 
University Hospital, Oslo, Norway 
Backgrounet Treatment wth Spironolactone (SPL) is beneficial in patients with severe 
congestive heart failure (CHF). In the RALES-trial SPL was well tolerated, particularly 
with regard to renal function and serum-@ levels. 
Aim: To investigate whether the reported low frequency of adverse effects during SPL 
treatment in a heart failure population could be confirmed in an unselected heart failure 
outpatient cohort 
Methods: We investigated 125 consecutive patients with CHF recruited from our heart 
failure clinic. Inclusion criteria were LVEF ~45% and treatment with SPL. Mean age was 
72.9 yrs (range 46.5-90.6), 27 4 % were women. NYHA-class distribution was: I: 5.7 %; 
II: 43.9 %; Ill: 46.3 % and IV. 4.1 %. Mean EF was 28 8 +/- 4.5%. Other medications 
included ACE-I in 64.0% and betablockers in 32.6%. Blood tests were performed 
monthly or more frequently If necessary. 
Results At baselme creatinme levels were 117.4+X5 (mean+/-SD; mmolll, normal 
~130) and serum-Q was 4.1+/-0.3 mmolll. The mean follow-up period was 11 months, 
and the cumulative observation period was 73 SPL treatment yrs. 60 pts. were already 
on SPL when admitted to the CHF clinic, with >30% receiving >25 mgld. The remainder 
were Initiated on SPL, with 9% receiving a dose >25 mg/d. During the follow-up period a 
total of 30.0% of the pts. developed hyperkalemia (>5 mmolll), wth 6.3% having serum- 
Kf >6 mmol/l. 53.3% of all patients had an increase of s-creatimne of z-20%, and 23.3% 
increased >50%. These alterations in s-creatinins and serum-@ were not significantly 
more frequent in patients treated with ACE-I or betablokkers or high-dose SPL (>I00 mg/ 
d). 
Conclusion SPL adverse effects (ImpaIred renal function, increase in s-K+) are much 
more prevalent in our elderly CHF patient population than prewously reported. Care 
should be gwen to the continuous monitoring of electrolytes and renal parameters. 
1106-124 Valsartan Produces a Sustained Decrease in Plasma 
Aldosterone Independent of Age, Gender, or Race: 
Results From Val-HeFT 
Roberto LatInI, lnderjit S Anand, Henry Krum, Serge Masson, Monica Salio, Robert 
Glazer, Yue Zhao, Jay Cohn, on behalf of the Val-HeFT Investigators, lstituto Mario 
Negn, Milan, Italy, University of Minnesota, Minneapolis. MN 
Background: Increase m plasma aldosterone in patients (pts) with heart failure (HF) 
may contrlbute to disease progression. Elevations of aldosterone occur frequently during 
effective ACE inhibition (&lsquotdbl;aldosterone escape&rsquotdbl;). We examined the 
effect of valsartan (V). an angiotensin receptor blocker, on aldosterone over time in pt 
subgroups based on gender, age. and race. Methods: Val-HeFT was a randomized, 
double-blind, placebo (P) controlled trial in 5,010 pts with HF, randomized to V or P. 
Aldosterone was measured at baseline and at least one post-baseline tlmepoint (4. 12, 
24 months) in 3,636 pts (male?.: 2,913; females: 723; ~65 yrs: 1,945; ~65 yrs: 1,691; 
blacks- 232; non-blacks: 3,404). Average aldosterone at baseline was 135 pg/mL for V 
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(n=l,607) and 146 pS/mL for P (n=l,629). For each subgroup, the effect of V on change 
from baseline in aldosterone was analyzed by ANCOVA. Results: P-subtracted least 
squares mean changes from baseline are presented (‘pcO.05 V vs. P). Significant reduc- 
tions in aldosterone from baseline were observed with V at 4, 12, 24 months and at end- 
point in males and females, elderly and non-elderly, and non-black pts. In the small and 
heterogeneous black subgroup, significant reductions in aldosterone were obsewed at 4 
and 12 months with beneficial trend at endpoint (p=O.O67). 
Conclusion: Val produced a sustained reduction in aldosterone in HF patients regard- 
less of age or gender or race. 
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1106-125 Inhibition of Both Neutral Endopeptidase and 
Endothelin Converting Enzyme Lowers Pulmonary 
Pressures in Congestive Heart Failure 
Kenneth Dickstein. Hanka de Vow4 Milutin Miric, Roland Willenbrock, Veselin Mitrovic, 
Richard Pacher, Gabriele Bambasek, Paul Koopman, University of Bergen, Central 
Hospital Ftogaland. Stavanger. Norway, Solvay Pharmaceuticals, Weesp, The 
Netherlands 
Background: SLV306 is an inhibitor of both’neutral endopeptidase and endothelin con- 
verting enzyme. In plasma it increases atrial natriurstic peptide levels and lowers endot- 
helin-1 levels. 
Methods: We studied 75 CHF patients (mean age 60.3 yrs. 91% male, 96% NYHA 
Class 11-111, ejection fraction 24 f 7%) in a double blind, placebo controlled, single oral 
dose hemodynamic study. The dose groups were: SLV306 200mg (n=l6), 400mg 
(n=20), 6OOmg (n=19), and placebo (n=l6). Hemodynamics were measured with a 
Swan-Ganz and anerial catheter for 12 hrs: other medication was withheld. 
Baseline mean hemodynamic values (n=75) were: systolic pulmonary artery pressure 
(SPAP) 44.7 * 16.9 mmf-lg, diastolic pulmonary arlely pressure (DPAP) 21.6 * 6.6 
mmHg, pulmonary capillaty wedge pressure (PCWP) 19.9 * 6.2 mmHg, mean arterial 
pressure (MAP) 93 * 15 mmHg. systemic vascular resistance (SVR) 1,610 + 476 
dynes&n?, and cardiac output (CO) 4.3 + 0.9 I/min. 
Results: Compared to placebo, pulmonary pressures significantly decreased in all 
SLV306 dose groups, with a maximum decrease 6 hrs post dose. No significant effects 
were found for MAP and CO. SVR decreased in the 200 and 6Mlmg_group, but did not 
separate from placebo. Hean rate did not change. 
Change from baseline 6 hrs posi 
dose 
200mg 400mg 600mg place 
bo 
SPAP mmHg -9.9. -11.7 -6.2 + -1.3 
DPAP mmHg -3.6’ -5.7’ -4.7’ -0.1 
PCWP mmHg -5.5’ -6.8’ -4.6+ -1.9 
MAP mmHg -4.4 -5.3 -6.4 -4.5 
SVFtdynessl -166 9 -244 -72 
crri) 
CO Ilmin 0.4 -0.2 0.1 0.1 
* p <0.05,+ p ~0.1 ANCOVA versus placebo 
Baseline adjusted AUC over 12 hrs 
200 400mg 800mg placebo 
mg 
-95’ -112 -72* -10 
-39’ -59’ -41* 4 
-51’ -69’ -&$+ -19 
-65 -68 -68 -47 
- -960 -2,472 -1,350 
2.61 
7 
4.7 -0.1 2.3 2.7 
Conclusion: SLV306 in doses of 200, 400, and BOOmg reduced pulmonary pressures. 
but without a clear dose response. Systemic pressures were maintained. Combined inhi- 
bibon of neutral endopeptidase and endothelin convening enzyme may be useful in CHF 
by lowering LV filling pressures. 
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1107-137 Cholesteryl Ester Transfer Protein Variants Are 
Associated With Plasma Levels of High-Density 
Lipoprotein Cholesterol but Not the Severity or 
Progression of Coronary Atherosclerosis or Response 
to Therapy 
Mehmet Cilineiroalu, Christie M. Ballantyne, Antonio M. Gotto, Jr., Ali J. Marian, Baylor 
College of Medicine, Houston, TX, Weil Medical College of Cornell University, New York, 
NY 
High-density lipoprotein cholesterol is inversely related to coronary atherosclerosis. 
Mutations in cholestelyl ester transfer protein (CEJP) lead to high levels of HDL-C but 
have been implicated in susceptibility to coronary atherosclerosis. We analyzed associa- 
tion of the two most common single nucleotide polymorphisms (SNP) in CETP, namely; 
279G/A and l405V (1394A/G) with plasma levels of HDL-C and other lipoproteins, sever- 
ity and progression of coronary atherosclerosis, response of lipids and atherosclerosis to 
treatment with fluvastatin and clinical outcome in a prospective 2.5 year follow-up study 
of 372 participants of Lipoprotein Coronary Atherosclerosis Study (LCAS). The 279G/A 
and l405V SNPs reoresent two separate common haolotvoes of the CETP rime. Geno- 
typing was performed by polymeiase chain reaction a& restriction map&g. CETP 
SNPs were stronalv associated with olasma levels of HDL-C 1279GIA: GG (n=lll~43.1. 
GA (11x176) 42.8and AA (n=65) 4i.6 mg/dl, p=O.O02) and i405V: II (n=150) 43.4, IV’ 
(n=160) 43.4 and VV (r&2) 46.6. p=O.O21) and similarly with apoA1 (p= 0.006 and 
0.016. respectively). Plasma levels of lowdensity lipoprotein cholesterol and apolipopro- 
teins were not significantly different among the genotypes. There were no association 
between baseline or final quantitative indices of severity of coronary atherosclerosis, 
minimum lumen diameter and the number of coronary lesions were not significantly dif- 
ferent among the genotypes. There were no significant treatment-by-genotype interac- 
tions between the genotypes of two SNPs and response of plasma lipids or coronary 
atherosclerosis to fluvastatin therapy. We conclude CETP SNPs, representing the two 
most common haplotypes. are associated with plasma levels of HDL-C but do not affect 
baseline severity, progression or regression of coronary atherosclerosis 01 response to 
therapy with fluvastatin. 
1107-138 Endothelial and Hepatic Lipase Gene Polymorphisms 
Are Associated With Plasma Levels of High-Density 
Lipoprotein Cholesterol in Lipoprotein Coronary 
Atherosclerosis Study 
Mehmet Cilinairoalu, Silvia Lutucuta, Suet Nee Chen, Antonio M. Gotto. Christie M. 
Ballantyne, Ali J. Marian, Baylor College of Medicine, Houston, TX, Weil Medical College 
of Cornell University, New York, NY 
Plasma level of high-density lipoprotein cholesterol (HDL-C), inversely associated with 
risk of coronary atherosclerosis, is under tight genetic control. It is estimated that at least 
50% of variance of HDL-C levels are genetically determined. However, genetic factors 
that determine plasma levels of HDL-C and thus, the risk of coronary atherosclerosis are 
largely unknown. Recently, a new member of lipase family, namely endothelial lipase 
(L/PC& has been cloned, which has a high homology to hepatic lipase (L/PO and regu- 
lates plasma levels of HDL-C. We analyzed association of two common single nucleotide 
polymorphisms (SNP) in LlPG and L/PC genes, namely; 564CTT SNP in LlPG and - 
514Cil in L/PC with plasma levels of HDL-C and other lipoproteins, severity and pro- 
gression of coronary atherosclerosis, response of lipids and atherosclerosis to treatment 
with fluvastatin and clinical outcome in a prospective 2.5 year follow-up study of 372 par- 
ticipants of LCAS. Genotyping was performed by polymerase chain reaction and restric- 
tion mapping and confirmed by sequencing. L/PC -514C/T SNP was associated with 
plasma levels of HDL-C (CC: 42.5 t 10.7 (n=222), CT: 46.3 + 12.5 (n=l26) and TT: 45.4 
+ 9.2 mg/dl (n=24), p=O.O12) and apolipoprotein (apo) Al (129.7 * 25.4 vs. 137.3 f 30.6 
vs. 140.0 f 20.0, respectively p=O.Ol) and showed a trend toward less severe coronary 
atherosclerosis. There was a modest genotype-by-treatment interaction for changes in 
plasma levels of HDL-C in response to fluvastatin. Baseline severity, progression or 
regression of coronary atherosclerosis were not significant different among the L/PC 
genotypes. Similarly, MPG 564Cfl SNP was associated with plasma levels of HDL-C 
(CC: 42.6 * 10.2 (,x165), CT: 44.7 * 12.2, TT: 49.6 + 13.5, p=O.O26) and modestly with 
apoA1 levels (p=O.O9). There were no significant genotype-by-treatment interactions 
between LIPG genotypes and response of plasma HDL-C to treatment or with baseline 
severity, progression or regression of coronary atherosclerosis. We conclude common 
L/PC and LlPG SNPs are associated with plasma levels of HDL-C. The L/PC SNP also 
showed a modest association with baseline severity of coronary atherosclerosis and 
response to therapy. 
